The scientist who discovered the AIDS virus has been busy working on a vaccine for the disease, and it has now begun human trials.
Robert Gallo, alongside a team University of Maryland School of Medicine, launched it’s Phase 1 clinical trial on Thursday last week.
Robert said in an official statement: “Our HIV/AIDS vaccine candidate is designed to bind to the virus at the moment of infection, when many of the different strains of HIV found around the world can be neutralized. We believe this mechanism is a major prerequisite for an effective HIV preventive vaccine.”
Robert and his team have been hard at work developing the vaccine for 15 years, and it has already undergone extensive testing on monkeys.
“While we still have more important basic research to do to crack the antibody protection challenge, this first step is an important one for us to learn how people (rather than test animals) respond.”
The immunogen in question, Full-Length Single Chain, is designed to elicit strong protective antibody reactions across the spectrum of HIV-1 strains.
This trial is probably just the beginning of the human testing stage, as it’s being tested on 60 people to assess the safety and immune responses of the vaccine.